Osagrand (Ibandronic Acid Monosodium Salt, Monohydrate)

Ibandronate, the active ingredient in Osagrand, is a bisphosphonate presented as a solid dosage form for oral use. It treats osteoporosis and other bone‑loss conditions in post‑menopausal women and men at risk of fractures. GNH USA supplies Osagrand as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Osagrand as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Osagrand is a bisphosphonate that acts on bone metabolism to reduce skeletal-related events.

- Osteoporosis: helps reduce the risk of vertebral and non‑vertebral fractures. - Paget's disease of bone: normalises bone turnover and alleviates pain. - Bone metastases from solid tumours: decreases skeletal complications and pain. - Hypercalcaemia of malignancy: lowers elevated serum calcium levels. - Steroid‑induced bone loss: mitigates loss of bone mineral density associated with long‑term glucocorticoid therapy. - Osteopenia: supports maintenance of bone density in at‑risk individuals.

Common Side Effects: -   g     ewline

-  ...